Matching articles for "spironolactone"

Aprocitentan (Tryvio) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 10, 2024;  (Issue 1704)
The FDA has approved the dual endothelin receptor antagonist aprocitentan (Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure...
The FDA has approved the dual endothelin receptor antagonist aprocitentan (Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is not adequately controlled on other drugs. Three other dual endothelin receptor antagonists, ambrisentan (Volibris, and generics), bosentan (Tracleer, and generics), and macitentan (Opsumit), are available in the US for treatment of pulmonary arterial hypertension.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):92-3 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024;  (Issue 1703)
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 | Show Full IntroductionHide Full Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • February 5, 2024;  (Issue 1695)
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in...
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 | Show Full IntroductionHide Full Introduction

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral...
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6 | Show Full IntroductionHide Full Introduction

In Brief: Oral Minoxidil for Hair Loss

   
The Medical Letter on Drugs and Therapeutics • December 26, 2022;  (Issue 1666)
Topical minoxidil (Rogaine, and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that...
Topical minoxidil (Rogaine, and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that off-label use of a low dose of oral minoxidil may also be effective.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):208 | Show Full IntroductionHide Full Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • December 27, 2021;  (Issue 1640)
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • June 14, 2021;  (Issue 1626)
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF...
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96 | Show Full IntroductionHide Full Introduction

Vericiguat (Verquvo) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • March 8, 2021;  (Issue 1619)
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a...
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas), which is FDA-approved for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, was the first.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):36-7 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • March 8, 2021;  (Issue 1619)
...
View the Comparison Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 | Show Full IntroductionHide Full Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • November 30, 2020;  (Issue 1612)
Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment...
Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of acne were last published in 2016.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):188-91 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 18, 2020;  (Issue 1598)
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2020 May 18;62(1598):73-80 | Show Full IntroductionHide Full Introduction

Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • March 23, 2020;  (Issue 1594)
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and...
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and antimineralocorticoid activity that could cause hyperkalemia. We should have added that concurrent use of drospirenone with other drugs that increase potassium levels, such as the anti-androgen aldosterone receptor antagonist spironolactone (Aldactone, and generics), which is often used off-label for treatment of acne, can increase the risk of hyperkalemia.
Med Lett Drugs Ther. 2020 Mar 23;62(1594):48 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • April 8, 2019;  (Issue 1569)
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are...
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF). There is little evidence that drug treatment improves clinical outcomes in patients with HFpEF.
Med Lett Drugs Ther. 2019 Apr 8;61(1569):49-54 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • April 8, 2019;  (Issue 1569)
...
View the Expanded Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2019 Apr 8;61(1569):e57-62 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 13, 2017;  (Issue 1516)
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2017 Mar 13;59(1516):41-8 | Show Full IntroductionHide Full Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • February 1, 2016;  (Issue 1487)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promotes development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):13-5 | Show Full IntroductionHide Full Introduction

Sacubitril/Valsartan (Entresto) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • August 3, 2015;  (Issue 1474)
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular...
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • January 19, 2015;  (Issue 1460)
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure...
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.
Med Lett Drugs Ther. 2015 Jan 19;57(1460):9-13 | Show Full IntroductionHide Full Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • August 4, 2014;  (Issue 1448)
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine...
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease.

FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol, Asacol HD, Lialda, and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine (Azulfidine, and generics), balsalazide (Colazal, and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa, and generics) and as a rectal suppository (Canasa).
Med Lett Drugs Ther. 2014 Aug 4;56(1448):65-72 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • January 1, 2013;  (Issue 125)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2013 Jan;11(125):1-8 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • September 1, 2012;  (Issue 121)
Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no...
Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no evidence that drug treatment of heart failure with preserved systolic function (LVEF >40%) improves clinical outcomes. Some of the drugs commonly used now for treatment of chronic heart failure are listed in the table on page 71.
Treat Guidel Med Lett. 2012 Sep;10(121):69-72 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2012;  (Issue 113)
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Treat Guidel Med Lett. 2012 Jan;10(113):1-10 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • July 1, 2009;  (Issue 83)
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as...
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
Treat Guidel Med Lett. 2009 Jul;7(83):53-6 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2009;  (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Treat Guidel Med Lett. 2009 Jan;7(77):1-10 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • November 1, 2008;  (Issue 75)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2008 Nov;6(75):75-82 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of Heart Failure

   
The Medical Letter on Drugs and Therapeutics • January 1, 2006;  (Issue 41)
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the...
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Treat Guidel Med Lett. 2006 Jan;4(41):1-4 | Show Full IntroductionHide Full Introduction

BiDil for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • September 28, 2005;  (Issue 1218)
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral...
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Med Lett Drugs Ther. 2005 Sep 28;47(1218):77-8 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • July 1, 2005;  (Issue 35)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2005 Jul;3(35):49-56 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 1, 2005;  (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Treat Guidel Med Lett. 2005 Jun;3(34):39-48 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • August 1, 2004;  (Issue 24)
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the...
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the convenience of highly effective contraceptive products. Like oral contraceptives and most barrier contraceptives, these devices do not protect against sexually transmitted diseases.
Treat Guidel Med Lett. 2004 Aug;2(24):55-62 | Show Full IntroductionHide Full Introduction

Blue light (ClearLight) for Acne Vulgaris

   
The Medical Letter on Drugs and Therapeutics • June 23, 2003;  (Issue 1159)
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review...
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Med Lett Drugs Ther. 2003 Jun 23;45(1159):50-1 | Show Full IntroductionHide Full Introduction

Eplerenone (Inspra)

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003;  (Issue 1156)
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of...
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.
Med Lett Drugs Ther. 2003 May 12;45(1156):39-40 | Show Full IntroductionHide Full Introduction

Insulin-Sensitizing Drugs for Polycystic Ovary Syndrome

   
The Medical Letter on Drugs and Therapeutics • April 28, 2003;  (Issue 1155)
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin...
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin resistance. In recent years, antidiabetic drugs, although not approved for such use by the FDA, have been tried for treatment of this disorder. This review describes the effectiveness of metformin and the thiazolidinediones in women with PCOS. Also included is a dosage and cost table for some insulin-sensitizing drugs.
Med Lett Drugs Ther. 2003 Apr 28;45(1155):35-6 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of Heart Failure

   
The Medical Letter on Drugs and Therapeutics • April 1, 2003;  (Issue 8)
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as...
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19.
Treat Guidel Med Lett. 2003 Apr;1(8):53-6 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • February 1, 2003;  (Issue 6)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Treat Guidel Med Lett. 2003 Feb;1(6):33-40 | Show Full IntroductionHide Full Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • June 24, 2002;  (Issue 1133)
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 12, 1999;  (Issue 1048)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Med Lett Drugs Ther. 1999 Mar 12;41(1048):23-8 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • January 29, 1999;  (Issue 1045)
...
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Med Lett Drugs Ther. 1999 Jan 29;41(1045):12-4 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • October 11, 1996;  (Issue 985)
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on...
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Med Lett Drugs Ther. 1996 Oct 11;38(985):92-4 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 14, 1993;  (Issue 896)
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs...
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs that decrease cardicac preload and afterload and those that increase contractility are commonly used together.
Med Lett Drugs Ther. 1993 May 14;35(896):40-2 | Show Full IntroductionHide Full Introduction

Quinapril for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 20, 1992;  (Issue 866)
Quinapril (Accupril - Parke-Davis), an angiotensin-converting enzyme (ACE) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of hypertension. ACE inhibitors are now...
Quinapril (Accupril - Parke-Davis), an angiotensin-converting enzyme (ACE) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of hypertension. ACE inhibitors are now widely used for this indication (Medical Letter, 33:33, 1991).
Med Lett Drugs Ther. 1992 Mar 20;34(866):27-8 | Show Full IntroductionHide Full Introduction

Three New ACE Inhibitors For Hypertension

   
The Medical Letter on Drugs and Therapeutics • September 6, 1991;  (Issue 852)
Benazepril (Lotensin - Ciba-Geigy), fosinopril (Monopril - Mead Johnson), and - Hoechst, Upjohn) are new angiotensin-converting enzyme (ACE) inhibitors recently approved by the US Food and Drug Administration...
Benazepril (Lotensin - Ciba-Geigy), fosinopril (Monopril - Mead Johnson), and - Hoechst, Upjohn) are new angiotensin-converting enzyme (ACE) inhibitors recently approved by the US Food and Drug Administration (FDA) for once-a-day treatment of hypertension. Three other ACE inhibitors, captopril (Capoten), enalapril (Vasotec), and lisinopril (Prinivil, Zestril) were previously available in the USA for this indication. Captopril and enalapril have also been approved by the FDA for treatment of congestive heart failure.
Med Lett Drugs Ther. 1991 Sep 6;33(852):83-4 | Show Full IntroductionHide Full Introduction

Lisinopril For Hypertension

   
The Medical Letter on Drugs and Therapeutics • April 8, 1988;  (Issue 763)
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors,...
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril (Capoten - Squibb) and e
Med Lett Drugs Ther. 1988 Apr 8;30(763):41-2 | Show Full IntroductionHide Full Introduction